---
title: |
  Investigating genetic modifications to enhance L1CAM-CAR T cell migration in solid tumors in a 3D bioprinted neuroblastoma model
authors:
  - "Lena Andersch"
  - "Laura Grunewald"
  - "Maria Stecklum"
  - "Filippos Klironomos"
  - "Kerstin Haase"
  - "Viola Hollek"
  - "Tobias Lam"
  - "Beate Anahita Jung"
  - "Anika Winkler"
  - "Silke Schwiebert"
  - "Kathy Astrahantseff"
  - "Michael Launspach"
  - "Marvin Jens"
  - "Anton Henssen"
  - "Lutz Kloke"
  - "Nils Blüthgen"
  - "Angelika Eggert"
  - "Johannes H. Schulte"
  - "Kathleen Anders"
  - "Annette Künkele"
year: 2025
journal: "Frontiers in Immunology"
doi: "10.3389/fimmu.2025.1677361"
url: "https://doi.org/10.3389/fimmu.2025.1677361"
lab: "berlin-bccn"
faculty:
  - "Nils Blüthgen"
tags:
  - "publication"
  - "berlin-bccn"
abstract: |
  <jats:sec>
                      <jats:title>Introduction</jats:title>
                      <jats:p>
                        Effective CAR T cell infiltration into solid tumors remains a major barrier to therapy success. Despite their clinical potential, few studies have evaluated phenotypes of CAR T cells successfully invading the tumor mass following infusion. Phenotypic information would enrich our understanding of the mechanisms governing CAR T cell migration into solid tumors. Here we implemented an
                        <jats:italic>in vitro</jats:italic>
                        strategy to identify genes driving L1CAM-CAR T cell migration into a 3D tumor mass.
                      </jats:p>
                    </jats:sec>
                    <jats:sec>
                      <jats:title>Methods</jats:title>
                      <jats:p>L1CAM-CAR T cells were separated into 2 groups by their capability to infiltrate (or not) a 3D bioprinted neuroblastoma model. Single-cell and bulk RNA sequencing was performed, and infiltrating CAR T cells were compared to noninfiltrating cells to seek genetic drivers of CAR T cell migration. CRISPR/Cas9 technology was used to generate modified L1CAM-CAR T cells.</jats:p>
                    </jats:sec>
                    <jats:sec>
                      <jats:title>Results</jats:title>
                      <jats:p>
                        Tumor-infiltrating L1CAM-CAR T cells expressed lower levels of the selectin P ligand (SELPLG) glycoprotein and higher levels of the T cell-specific adaptor protein, SH2D2A. Functional characterization of L1CAM-CAR T cells genetically modified to enforce these characteristics demonstrated that neither trait negatively impacted L1CAM-CAR T cell cytotoxicity, activation and cytokine release upon coculture with neuroblastoma target cells. Transgenic SH2D2A expression did not improve CAR T cell migration in an endothelial transmembrane assay. SELPLG knockout benefited CAR T cell
                        <jats:italic>in vitro</jats:italic>
                        trans-endothelial migration, but did not enhance anti-tumor efficacy in an immunodeficient mouse model.
                      </jats:p>
                    </jats:sec>
                    <jats:sec>
                      <jats:title>Discussion</jats:title>
                      <jats:p>
                        Our findings reveal a key limitation of murine xenograft models, which are widely used as the gold standard for preclinical CAR T cell testing. The lack of conservation between the human and murine SELPLG proteins likely accounts for the discrepancy between enhanced
                        <jats:italic>in vitro</jats:italic>
                        migration of SELPLG-deficient L1CAM-CAR T cells and their lack of improved efficacy in the mouse model. This underscores the need for more predictive human-relevant models to better preclinically evaluate CAR T cell function.
                      </jats:p>
                    </jats:sec>
fulltext_available: false
fulltext_source: "none"
created: "2025-12-01T09:34:45.841480"
---

# Investigating genetic modifications to enhance L1CAM-CAR T cell migration in solid tumors in a 3D bioprinted neuroblastoma model

## Abstract

<jats:sec>
                    <jats:title>Introduction</jats:title>
                    <jats:p>
                      Effective CAR T cell infiltration into solid tumors remains a major barrier to therapy success. Despite their clinical potential, few studies have evaluated phenotypes of CAR T cells successfully invading the tumor mass following infusion. Phenotypic information would enrich our understanding of the mechanisms governing CAR T cell migration into solid tumors. Here we implemented an
                      <jats:italic>in vitro</jats:italic>
                      strategy to identify genes driving L1CAM-CAR T cell migration into a 3D tumor mass.
                    </jats:p>
                  </jats:sec>
                  <jats:sec>
                    <jats:title>Methods</jats:title>
                    <jats:p>L1CAM-CAR T cells were separated into 2 groups by their capability to infiltrate (or not) a 3D bioprinted neuroblastoma model. Single-cell and bulk RNA sequencing was performed, and infiltrating CAR T cells were compared to noninfiltrating cells to seek genetic drivers of CAR T cell migration. CRISPR/Cas9 technology was used to generate modified L1CAM-CAR T cells.</jats:p>
                  </jats:sec>
                  <jats:sec>
                    <jats:title>Results</jats:title>
                    <jats:p>
                      Tumor-infiltrating L1CAM-CAR T cells expressed lower levels of the selectin P ligand (SELPLG) glycoprotein and higher levels of the T cell-specific adaptor protein, SH2D2A. Functional characterization of L1CAM-CAR T cells genetically modified to enforce these characteristics demonstrated that neither trait negatively impacted L1CAM-CAR T cell cytotoxicity, activation and cytokine release upon coculture with neuroblastoma target cells. Transgenic SH2D2A expression did not improve CAR T cell migration in an endothelial transmembrane assay. SELPLG knockout benefited CAR T cell
                      <jats:italic>in vitro</jats:italic>
                      trans-endothelial migration, but did not enhance anti-tumor efficacy in an immunodeficient mouse model.
                    </jats:p>
                  </jats:sec>
                  <jats:sec>
                    <jats:title>Discussion</jats:title>
                    <jats:p>
                      Our findings reveal a key limitation of murine xenograft models, which are widely used as the gold standard for preclinical CAR T cell testing. The lack of conservation between the human and murine SELPLG proteins likely accounts for the discrepancy between enhanced
                      <jats:italic>in vitro</jats:italic>
                      migration of SELPLG-deficient L1CAM-CAR T cells and their lack of improved efficacy in the mouse model. This underscores the need for more predictive human-relevant models to better preclinically evaluate CAR T cell function.
                    </jats:p>
                  </jats:sec>

## Links

- DOI: [10.3389/fimmu.2025.1677361](https://doi.org/10.3389/fimmu.2025.1677361)
- URL: [Link](https://doi.org/10.3389/fimmu.2025.1677361)

## Faculty

- [[berlin-bccn/faculty#nils-blüthgen|Nils Blüthgen]]
